Skip to main content
PBLSParabilis Medicines, Inc.Sell5.3·$27.44
SellModerate Confidence
Investment thesis

Parabilis Medicines cannot currently be evaluated on price-based measures due to a missing price feed, and the available fundamentals point to margin compression, insider selling, and below-average quality that argue for caution once trading data is restored.

Thesis pillars

  • Value Trap Signals Margin And Insider Selling→Stable
  • Data Outage Blocks Trade Setup→Stable
  • Quality Concerns Flagged→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Jul 5, 2026· older than 90 days

Full reasoning →

Open full analysis

Parabilis Medicines, Inc. (PBLS) Stock Analysis

Range Bound setup

SellVALUE-TRAP 1/5QualityModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $27.44: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.36; Below-average business quality.

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that... Read more

$27.44+30.0% A.UpsideScore 5.3/10#105 of 240 Biotechnology
QualityF-score4 / 9FCF yield—
Stop $25.52Analyst target $35.67(−13% haircut)A.R:R 2.0:1
Analyst consensus$41.00+49.4%6 analysts with price targets
$35.67Analyst target
$27.44price
$41.00mean
$45

Sell if holding. Engine safety override at $27.44: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.36; Below-average business quality. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 116d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated Nov 12, 2026

Recent Developments — Parabilis Medicines, Inc.

Latest item Nov 12, 2026 · Generated 2026-11-22T11:57:10Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Mar 18, 2027116d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.0 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-11.6
Mkt Cap$3.4B
EV/EBITDA-13.7
Profit Mgn0.0%
ROE—
Rev Growth—
Beta—
DividendNone
Analysts with ratings12

Quality Signals

Piotroski F4/9MoatNarrow

Options Flow

P/C2.36bearish
IV107%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·1 ceiling hit

Volatile — 7.0% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Put Call
0.0
Implied Vol
0.0
Days To Cover
0.4
Short Interest
5.5
Debt Equity
9.8
Elevated put/call: 2.36High IV: 107%

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Gross Margin
0.0
Net Margin
0.0
Piotroski F
4.4
Current Ratio
5.0
Moat
5.5
Quality concerns

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
0.0
Earnings History
3.3
Erm
5.0
Earnings Timing
5.0
GatesMomentum 4.2<4.5A.R:R 2.0 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 116d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Speculative
RSI
51 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MASupport $23.06Resistance $31.49

Price Targets

$26
$36
A.Upside+30.0%
A.R:R2.0:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Quality below floor (3.0 < 4.0)
! momentum at 4.2 (below the engine's 4.5 threshold)

Earnings

B
M
M
M
1/4 beats
Next Earnings2027-03-18 (116d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is PBLS stock a buy right now?

Sell if holding. Engine safety override at $27.44: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.36; Below-average business quality. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $25.52. Score 5.3/10, moderate confidence.

What is the PBLS stock price target?

Analyst target: $35.67 (+30.0% upside). Prior stop was $25.52. Stop-loss: $25.52.

What are the risks of investing in PBLS?

Quality below floor (3.0 < 4.0).

Is PBLS overvalued or undervalued?

Parabilis Medicines, Inc. trades at a P/E of N/A (forward -11.6). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about PBLS?

12 analysts rate PBLS, with a consensus score of 4.3/5. 6 analysts publish price targets averaging $41.

What does Parabilis Medicines, Inc. do?Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide...

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Related stocks: ZVRA (Zevra Therapeutics, Inc.) · PHAT (Phathom Pharmaceuticals, Inc.) · HALO (Halozyme Therapeutics, Inc.) · ADRX (ADARx Pharmaceuticals, Inc.) · ASND (Ascendis Pharma A/S)
Home › Stocks › PBLS

Latest news

Latest News

Fiscal.ai10d ago
Benzinga10d ago
Benzinga13d ago
Fiscal.ai13d ago
Fiscal.ai16d ago
Fiscal.ai19d ago
Benzinga28d ago
Fiscal.ai29d ago
Fiscal.ai31d agoAnalyst
Benzinga31d ago
Benzinga34d ago
Benzinga34d ago
Benzinga39d agoProduct
Benzinga66d ago
Benzinga101d ago
Benzinga139d ago
Benzinga139d agoAnalyst
Benzinga139d ago